Sugi Predict

Sugi Predict / Compounds / SCHEMBL6082229

SCHEMBL6082229

SCHEMBL6082229

CN(C=O)c1cccc(NC(=O)Oc2ccccc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 2/20 0.64
▸ ACHE P22303 1/20 0.64
▸ CYP1A2 P05177 1/20 0.59
▸ ALDH1A1 P00352 7/20 0.57
▸ MAPT P10636 4/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ THRB P10828 1/20 0.57
▸ GFER P55789 1/20 0.57
▸ TDP1 Q9NUW8 1/20 0.57
▸ GAA P10253 2/20 0.50
▸ HTT P42858 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ RAD51 Q06609 1/20 0.49
▸ POLB P06746 1/20 0.48
▸ FAAH O00519 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ RAB9A P51151 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2475633 0.86 BCHE (0.84) BCHEACHECYP1A2ALDH1A1MAPT
SCHEMBL27526014 0.84 BCHE (0.60) BCHEACHECYP1A2ALDH1A1MAPT
SCHEMBL8048626 0.80 CYP1A2 (0.76) BCHEACHECYP1A2ALDH1A1MAPT
Hydrochloric Acid SCHEMBL29406709 0.77 BCHE (0.97) BCHEACHECYP1A2ALDH1A1MAPT
SCHEMBL10062253 0.76 CYP1A2 (0.62) BCHEACHECYP1A2ALDH1A1MAPT
Phenyl M-Tolylcarbamate SCHEMBL259420 0.76 ALDH1A1 (0.78) BCHEACHECYP1A2ALDH1A1MAPT
SCHEMBL18842378 0.76 CYP1A2 (0.70) BCHEACHECYP1A2ALDH1A1MAPT
Phenyl M-Tolylcarbamate SCHEMBL29739712 0.76 ALDH1A1 (0.78) BCHEACHECYP1A2ALDH1A1MAPT
SCHEMBL3983838 0.76 ALDH1A1 (0.73) CYP1A2ALDH1A1KMT2AMEN1GAA
SCHEMBL5338427 0.76 CYP1A2 (0.74) BCHEACHECYP1A2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6984651-B2 Piperidine amides as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA, COMPANY (US) 2006-01-10 — — US disclosed
US-20040082790-A1 Piperidine amides as modulators of chemokine receptor activity DUNCIA JOHN V (US) 2004-04-29 — — US disclosed
US-6638950-B2 Antiasthmatics and antiallergens, treating autoimmune pathologies such as rheumatoid arthritis and atherosclerosis BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-10-28 — — US disclosed
US-20020156102-A1 Piperidine amides as modulators of chemo kine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156102-A1 Piperidine amides as modulators of chemo kine receptor activity CCR3, CCR1, ACKR3 BCHE 4293/4885ACHE 4538/4885CYP1A2 4104/4885
US-20040082790-A1 Piperidine amides as modulators of chemokine receptor activity CCR3, CCR1, CCL11 BCHE 3052/4885ACHE 3976/4885CYP1A2 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.